6 research outputs found
Targeting the Malaria Parasite cGMP-Dependent Protein Kinase to Develop New Drugs.
The single-celled apicomplexan parasite Plasmodium falciparum is responsible for the majority of deaths due to malaria each year. The selection of drug resistance has been a recurring theme over the decades with each new drug that is developed. It is therefore crucial that future generations of drugs are explored to tackle this major public health problem. Cyclic GMP (cGMP) signaling is one of the biochemical pathways that is being explored as a potential target for new antimalarial drugs. It has been shown that this pathway is essential for all of the key developmental stages of the complex malaria parasite life cycle. This gives hope that targeting cGMP signaling might give rise to drugs that treat disease, block its transmission and even prevent the establishment of infection. Here we review previous work that has been carried out to develop and optimize inhibitors of the cGMP-dependent protein kinase (PKG) which is a critical regulator of the malaria parasite life cycle
Development of Chemical Entities Endowed with Potent Fast-Killing Properties against Plasmodium falciparum Malaria Parasites.
One of the attractive properties of artemisinins is their extremely fast-killing capability, quickly relieving malaria symptoms. Nevertheless, the unique benefits of these medicines are now compromised by the prolonged parasite clearance times and the increasing frequency of treatment failures, attributed to the increased tolerance of Plasmodium falciparum to artemisinin. This emerging artemisinin resistance threatens to undermine the effectiveness of antimalarial combination therapies. Herein, we describe the medicinal chemistry efforts focused on a cGMP-dependent protein kinase (PKG) inhibitor scaffold, leading to the identification of novel chemical entities with very potent, similar to artemisinins, fast-killing potency against asexual blood stages that cause disease, and activity against gametocyte activation that is required for transmission. Furthermore, we confirm that selective PKG inhibitors have a slow speed of kill, while chemoproteomic analysis suggests for the first time serine/arginine protein kinase 2 (SRPK2) targeting as a novel strategy for developing antimalarial compounds with extremely fast-killing properties
Pharmacophore Mapping of Thienopyrimidine-Based Monophosphonate (ThP-MP) Inhibitors of the Human Farnesyl Pyrophosphate Synthase
The
human farnesyl pyrophosphate synthase (hFPPS), a key regulatory
enzyme in the mevalonate pathway, catalyzes the biosynthesis of the
C-15 isoprenoid farnesyl pyrophosphate (FPP). FPP plays a crucial
role in the post-translational prenylation of small GTPases that perform
a plethora of cellular functions. Although hFPPS is a well-established
therapeutic target for lytic bone diseases, the currently available
bisphosphonate drugs exhibit poor cellular uptake and distribution
into nonskeletal tissues. Recent drug discovery efforts have focused
primarily on allosteric inhibition of hFPPS and the discovery of non-bisphosphonate
drugs for potentially treating nonskeletal diseases. Hit-to-lead optimization
of a new series of thienopyrimidine-based monosphosphonates (ThP-MPs)
led to the identification of analogs with nanomolar potency in inhibiting
hFPPS. Their interactions with the allosteric pocket of the enzyme
were characterized by crystallography, and the results provide further
insight into the pharmacophore requirements for allosteric inhibition